MNPR Earnings Date: Nov 12, 2026 (Estimated) — Monopar Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is MNPR's next earnings date?
Monopar Therapeutics Inc. (MNPR) is expected to report Q3 2026 earnings on Thursday, November 12, 2026 at 8:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.86.
How did MNPR do in its last earnings report?
In its most recent report on Aug 12, 2026 (Q2 2026), Monopar Therapeutics Inc. posted EPS of -$0.62 versus the -$0.64 estimate, a beat of 4.6%. Revenue was $0. The stock's 1-day post-earnings move was +0.4%.
How much does MNPR stock move after earnings?
MNPR beat EPS estimates in 4 of its last 7 reported quarters. Over the last 8 reports the stock moved an average of 7.3% (up or down) in the day after earnings.
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q2 2026 | -0.64 | -0.62 | +4.62% | $0 | ✅ Beat | +0.38% | +4.01% | -3.93% |
| 2026-05-14 | Q1 2026 | -0.93 | -0.46 | +50.54% | $0 | ✅ Beat | -0.73% | +5.71% | -2.72% |
| 2026-03-27 | Q4 2025 | -0.54 | -0.61 | -12.96% | $0 | ❌ Miss | -0.84% | +1.04% | -0.99% |
| 2025-11-13 | Q3 2025 | -0.42 | -0.48 | -14.29% | $0 | ❌ Miss | +5.36% | +0.51% | -9.66% |
| 2025-08-12 | Q2 2025 | -0.48 | -0.35 | +27.08% | $0 | ✅ Beat | +14.55% | +9.32% | +36.89% |
| 2025-03-31 | Q4 2024 | — | -2.23 | — | $0 | — | -9.72% | -25.61% | +4.04% |
| 2024-11-08 | Q3 2024 | -0.48 | -0.37 | +22.92% | $0 | ✅ Beat | +7.31% | +15.89% | +41.64% |
| 2024-08-09 | Q2 2024 | -0.45 | -0.50 | -11.11% | $0 | ❌ Miss | -19.64% | -13.82% | -12.73% |
Showing last 8 quarters.